



Figure 2 Detail of an area of fibrinoid necrosis surrounded by a palisade of histiocytes; infiltration predominantly with lymphocytes and plasma cells (haematoxylin and eosin). Bar represents 25 μ m.

changes of fibrosis and necrosis. Valvular involvement has been described in patients with all types of JIA,³ the aortic valve being most commonly affected.⁴⁻⁹ Valvular disease is associated with severe destructive articular disease.⁴⁻⁷

Furthermore, our case report confirms the possibility of successful mechanical aortic valve replacement in a case of severe progressive aortic valve insufficiency and secondary angina pectoris in a patient with polyarticular JIA.

We recommend regular cardiac appraisal as part of the routine assessment of every patient with JIA. Whenever cardiac murmurs are detected in these patients, echocardiographic assessment should be considered, because if there is valve insufficiency the cardiac function may deteriorate and cardiac surgery may be needed.

Acknowledgments

We are grateful to Dr J van der Meulen, cardiothoracic surgeon, for the surgical description and to Dr AC van der Wal, pathologist, for his pathology specimen evaluation. We thank Dr FM Westerweel, rheumatologist, for allowing us to report on her patient.

I E M Bultink, W F Lems, B A C Dijkmans, R M van Soesbergen

Department of Rheumatology, Slotervaart Hospital, Amsterdam, Jan van Breemen Institute, Amsterdam, and Vrije Universiteit Medical Centre, Amsterdam, The Netherlands

J Lindeman

Department of Pathology, Slotervaart Hospital, Amsterdam, The Netherlands

Correspondence to: Dr I E M Bultink, Department of Rheumatology, Slotervaart Hospital, Louwesweg 6 1066 EC, Amsterdam, The Netherlands; iem_bultink@hotmail.com

References

- 1 Lie JT. *Biopsy diagnosis in rheumatic diseases*. New York, Tokyo: Igaku-Shoin, 1997.
- 2 Cassidy JT, Petty RE. *Textbook of pediatric rheumatology*. 3rd ed. Philadelphia: Saunders, 1995:154-6.

- 3 Barron KS. Cardiovascular manifestations of connective tissue diseases. In: Garson A, Bricker JT, McNamara DG, eds. *The science and practice of paediatric cardiology*. Vol 2. Philadelphia: Lea and Febiger, 1990:1527-41.
- 4 Leak AM, Millar-Craig MW, Ansell BM. Aortic regurgitation in seropositive juvenile arthritis. *Ann Rheum Dis* 1981;40:229-34.
- 5 Kramer PH, Imboden JB, Waldman FM, Turley K, Ports TA. Severe aortic insufficiency in juvenile chronic arthritis. *Am J Med* 1983;74:1088-91.
- 6 Delgado EA, Petty RE, Malleson PN, Patterson MWH, D'Orsonga L, LeBlanc J. Aortic valve insufficiency and coronary artery narrowing in a child with polyarticular juvenile rheumatoid arthritis. *J Rheumatol* 1988;15:144-7.
- 7 Heyd J, Glaser J. Early occurrence of aortic valve regurgitation in a youth with systemic-onset juvenile rheumatoid arthritis. *Am J Med* 1990;89:123-4.
- 8 Keeley SB, Brewer PL, Burdette FM. Homograft root replacement for juvenile rheumatoid aortic valve incompetence. *Ann Thorac Surg* 1992;53:330-1.
- 9 Boris JR, Hollister JR, Tyson RW, Wolfe RR. Severe aortic regurgitation with mechanical prosthetic valve replacement in pauciarticular juvenile rheumatoid arthritis. *J Rheumatol* 1998;25:1211-14.

Polymyalgia rheumatica and pericardial tamponade

Polymyalgia rheumatica causes symmetrical stiffness in the neck, shoulder, and pelvic girdles, and affects middle aged and elderly people, with a higher incidence among women. A group of systemic, non-specific complaints such as weight loss, moderate fever, asthenia, and persistent high erythrocyte sedimentation rate are other clinical features.

The association of polymyalgia rheumatica and pericardial effusion has already been described in two cases.^{1,2}

A 73 year old woman was admitted for the evaluation of pericardial effusion and mild anaemia. Polymyalgia rheumatica was suspected because the patient had had asthenia, stiffness, and pain in the shoulders and hips for about a year before coming to hospital. She had also lost 5 kg in a few months. A few days before admission she had presented worsening dyspnoea.

An echocardiogram showed large pericardial effusion and initial findings of cardiac tamponade (right atrial and right ventricular diastolic collapse), so a pericardiocentesis was done: polymerase chain reaction tests in the pericardial fluid for *Mycobacterium tuberculosis* and cultures for aerobes and anaerobes were negative; tumoral cells were absent. Serological tests for antibodies to cytomegalovirus, herpes simplex and Epstein-Barr viruses, anti-smooth muscle, antinuclear, anti-DNA, and anti-extractable nuclear antigen antibodies were negative; Schirmer's test and the break-up time were also normal. The erythrocyte sedimentation rate (ESR) was 130 mm/1st h and C reactive protein (CRP) was 85 mg/l.

The patient was first treated with indometacin (50 mg twice a day) for a week, with no improvement, and then with low doses of prednisone (10 mg/day): the symptoms markedly improved and the ESR and CRP dropped to 27 mm/1st h and 12 mg/l, respectively, in a few weeks. An echocardiogram a month later was negative for pericardial effusion; ESR and CRP were also normal.

The patient has remained entirely well after a follow up of one year.

The presenting symptoms (girdles bilateral and symmetrical stiffness and pain) accompanied by systemic features (fatigue, weight loss, raised ESR) and the marked improvement after prednisone confirm the diagnosis of polymyalgia rheumatica.

As far as we know this is the first report of pericardial tamponade requiring pericardial drainage in this disease.

A Brucato, G Brambilla

Divisione Medica "Brera", Ospedale Niguarda Ca' Granda, Milan, Italy

Correspondence to: Dr G Brambilla, Divisione Medica "Brera", Via Mameli 46, 20129, Milan, Italy; bramбил@iscalinet.it

References

- 1 Teira Cobo R, Zubero Sulibarria Z, Munoz Sanchez J, Santamaria Jauregi JM. Polymyalgia rheumatica and pericardial effusion. *Ann Med Interna* 1991;8:362-3.
- 2 Bohan A. Polymyalgia rheumatica and pericardial effusion. *Ann Intern Med* 1984;101:147.

Remission of Behçet's syndrome with TNF α blocking treatment

Goossens *et al* reported on a patient in whom a remission of Behçet's syndrome was induced with tumour necrosis factor (TNF) blocking treatment.¹ We would like to add our experience in a patient with Behçet's disease associated with rheumatoid arthritis (RA), treated with infliximab (Remicade).

A 47 year old male patient, born in Morocco, living in Israel, was diagnosed 14 years earlier with severe, progressive polyarthritides of hands, feet, and knees. Radiography showed articular bone erosions; rheumatoid factor was positive, with a high erythrocyte sedimentation rate and C reactive protein. In parallel, the patient reported recurrent buccal and genital ulcers two to three times a month with papulopustular skin lesions on the feet. HLA-B5 (51) was positive. There was no eye involvement. A diagnosis of Behçet's disease associated with erosive, seropositive RA was suggested. The patient was treated with sulfasalazine and colchicine without improvement; steroid treatment with auranofin was added. The disease was poorly controlled, with progressive erosions in hands, knees, and feet. Later, pulse steroids, methotrexate, azathioprine, and cyclosporin were added serially, either singly or in combination.

In subsequent years he became dependent on steroids and never achieved complete remission. In December 2000 the patient was admitted to hospital with severe active polyarthritides, flexion contractures of the elbows, and an especially swollen left knee with Baker's cyst and severe erosive disease. The patient additionally had buccal and penile ulcers. Because of the lack of response to conventional treatment we decided to treat him with infliximab (Remicade; Schering), a chimeric IgG monoclonal antibody directed against TNF. He received 300 mg intravenously (3 mg/kg) at intervals of two weeks, six weeks, and then every eight weeks. Two weeks after the first infusion the ulcers of mouth, penis, and other skin lesions were already considerably smaller and later disappeared. The polyarthritides improved considerably, except for the left knee, which required total replacement. Infliximab was given with continued colchicine and azathioprine. Our case, as in Goossens' report, suggests that infliximab may have a beneficial therapeutic effect in mucoserosal and cutaneous lesions as well as

synovitis in Behçet's disease, in our case in association with RA.

Controlled studies will be needed to assess adequately the full effect of TNF antagonists in Behçet's disease.

M Rozenbaum, I Rosner, E Portnoy

Department of Rheumatology, Bnai Zion Medical Centre, Technion Faculty of Medicine, Haifa, Israel

Correspondence to: Dr Rosner; rosner@tx.technion.ac.il

- 1 **Goossens PH**, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor a blocking therapy. *Ann Rheum Dis* 2001;60:637.

Fatigue and immune activity in Sjögren's syndrome

Despite major desiccation of mucous membranes in Sjögren's syndrome (SS), fatigue is often experienced by patients as the most disabling complaint.^{1,2} Unfortunately, there is no proper treatment available to combat the fatigue in SS. Beside a variety of somatic and non-somatic conditions,²⁻⁶ increased immune activity has been implicated as a cause of fatigue in autoimmune diseases.^{6,7} If responsible for fatigue in SS, it could serve as a treatment target. The purpose of this study was, therefore, to examine the relation between fatigue and immune variables in SS.

Thirty six consecutive patients with primary SS visiting our outpatient departments participated in this study. Two control groups were used: a group of 18 patients diagnosed with secondary SS, and a group of 34 non-medicated healthy controls. Diagnoses were based on the revised European criteria for the classification of SS.⁸ Control groups were matched for age and sex. Disease duration or treatment did not differ significantly between patients with primary and secondary SS. Patients with other chronic diseases were excluded from the study. The Dutch Fatigue Scale (DUFS) was used to quantify fatigue. This validated questionnaire poses nine questions about different aspects of fatigue (table 1).⁹ Because depression is frequently observed in SS,^{2,5} a standardised psychiatric questionnaire (SCL-90) was used to rule out this potential confounding variable for fatigue.¹⁰ Immunological activity was evaluated by assessing rheumatoid factor, antinuclear antibodies, presence of anti-SS-A and anti-SS-B, levels of immunoglobulins (IgG, IgM, and IgA), haemoglobin levels, leucocytes, thrombocytes, erythrocyte sedimentation rate, and C reactive protein (CRP). After preliminary analysis using correlation tests, the best model to explain fatigue was calculated by using multiple regression with forward selection (SPSS version 8.0). Independent Student *t* tests were used to compare the studied groups.

Fatigue was equally raised in patients with both primary and secondary SS, and differed significantly from that of healthy controls. Twenty one (58%) patients with primary SS scored "high" or "very high" out of the six categories for depression according to the SCL-90 criteria. These depression scores did not significantly differ from the scores in secondary SS patients. Further analysis showed that 79% of the fatigue in patients with primary SS could be explained by depression, total level of immunoglobulins, and thrombocyte counts ($p < 0.001$). Both depression and thrombocyte counts showed a significant positive correlation, whereas levels of immunoglobulins showed a negative correlation.

Though tempting as a treatment target, the immune and inflammatory variables failed to predict fatigue satisfactorily in primary SS. Levels of immunoglobulins showed, surprisingly, a significant negative correlation. Thrombocyte counts showed a significant positive correlation. Although increases in thrombocytes follow the acute phase reaction, no significant correlation between thrombocyte counts and CRP levels were found. A chance association between fatigue and thrombocyte counts as well as immunoglobulin levels seems thus possible. Therefore, the intriguing question whether immune or inflammatory activity is a causative factor of chronic fatigue in SS remains unravelled. Because no difference in fatigue was found between patients with primary and secondary SS, the presence of another autoimmune disease appears to have no additional effect on the amount of fatigue in SS. In agreement with findings of previous studies, a significant relation was found between the degree of fatigue and the level of depression in patients with primary SS.^{2,5} It is concluded that none of the laboratory variables reflecting immune activity predict fatigue satisfactorily in primary SS. Signs of depression, as present in most of the patients with primary SS, proved to be the most relevant cause of their exhausting fatigue. Therefore we recommend including a psychosomatic approach in the treatment of fatigue in primary SS.

H I Bax, T M Vriesendorp, C G M Kallenberg

Department of Clinical Immunology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands

W W I Kalk

Department of Oral and Maxillofacial Surgery, University Hospital Groningen

Correspondence to: Dr W W I Kalk, Department of Oral and Maxillofacial Surgery, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands; w.w.i.kalk@kchir.azg.nl

References

- 1 **Gudbjörnsson B**, Broman JE, Hetta J, Hällgren R. Sleep disturbances in patients with

primary Sjögren's syndrome. *Br J Rheumatol* 1993;32:1072-6.

- 2 **Barendregt PJ**, Visser MRM, Smets EMA, Tulen JHM, van den Meiracker AH, Boomsma F, *et al*. Fatigue in primary Sjögren's syndrome. *Ann Rheum Dis* 1998;57:291-5.
- 3 **Flescher E**, Talal N. Do viruses contribute to the development of Sjögren's syndrome? *Am J Med* 1991;90:283-5.
- 4 **Alexander EL**, Kumar AJ, Kozachuk WE. The chronic fatigue syndrome controversy [letter]. *Ann Intern Med* 1992;117:343-4.
- 5 **Bjerrum K**, Prause JU. Primary Sjögren's syndrome: a subjective description of the disease. *Clin Exp Rheumatol* 1990;8:283-8.
- 6 **Asim M**, Turney JH. The female patient with faints and fatigue: don't forget Sjögren's syndrome. *Nephrol Dial Transplant* 1997;12:1516-17.
- 7 **Wysenbeek AJ**, Leibovici L, Weinberger A, Guedj D. Fatigue in systemic lupus erythematosus. Prevalence and relation to disease expression. *Br J Rheumatol* 1993;32:633-5.
- 8 **Vitali C**, Bombardieri S, Moutsopoulos HM, Coll J, Gerli F, Hatzon PY, *et al*. The European classification criteria for Sjögren's syndrome (SS): proposal for a modification of the rules for classification suggested by the analysis of the receiver operating characteristic (ROC) curve of the criteria performance [abstract]. *J Rheumatol* 1997;24(suppl 50):38.
- 9 **Tiesinga LJ**, Dassen TVN, Halfens RJG. DUFS and DEFS: development, reliability and validity of the Dutch Fatigue Scale and the Dutch Exertion Fatigue Scale. *Int J Nurs Stud* 1998;35:115-23.
- 10 **Derogatis LR**, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale-preliminary report. *Psychopharmacol Bull* 1973;9:13-28.

BOOK REVIEW

Glucocorticoids

Eds N J Goulding, R J Flower. (Pp 216; DM240.) Basel: Birkhäuser, 2001. ISBN 3-7643-6059-3. (Milestones in drug therapy. Series editors M J Parnham, J Bruinvels.)

People are bound to think: Oh no! Is yet another book about drugs that we are using successfully every day really necessary? Well, the answer to this question is: Yes, it is! More than 50 years after the clinical introduction of these drugs, updates are necessary to establish *Milestones in drug therapy* (the title of the series published by Birkhäuser). Sometimes unnoticed by all who use glucocorticoids, new, not always spectacular, but still significant knowledge has been gained about these vital drugs and how they should be administered. The authors try to put this across in a readable form, which means that known information is recapitulated concisely and new information is included. A very good example are the chapters that deal with the basic mechanisms of action. However, the only real criticism also applies at this point: some comments are redundant and tighter editing would have improved individual contributions.

Renowned authors reflect upon the most important facets of treatment with glucocorticoids. These facets include the history as well as basic biology, the development of synthetic compounds, extensive discussions about the glucocorticoid receptor, the dynamics of cytokine and other gene regulations by glucocorticoids, the interrelationship between exogenous and endogenous steroids, and a clinical section which deals with the use of steroids in asthma, arthritis, and inflammatory bowel disease. Allan Munck, one of the

Table 1 Dutch Fatigue Scale.⁹ Each item is scored on a 1 to 4 point scale

1. Listlessness
2. Perceived need for additional energy to finish required tasks
3. Verbalisation of an unremitting and overwhelming lack of energy
4. Inability to restore energy, even after sleeping
5. Increase in rest requirements
6. Decreased libido
7. Inability to maintain usual routine
8. Impaired ability to concentrate
9. Decreased performance